RADNOR, Pa., Aug. 15, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Centene Corporation (“Centene”) (NYSE: CNC) on behalf of those who purchased or otherwise acquired Centene securities between December 12, 2024, and June 30, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is September 8, 2025. ...

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neogen Corporation (“Neogen” or “the Company”) (NASDAQ: NEOG) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neogen sec ...

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for alleged misrepresentations regarding its capital allocation priorities and risks associated with its product Nexplanon during the class period from November 3, 2022, to April 30, 2025 [1][3][4] Company Overview - Organon & Co. is a healthcare company based in Jersey City, NJ, focusing on women's health [2] - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2] Lawsuit Details - The lawsuit claims that despite increasing debt from the Dermavant acquisition, Organon assured investors it would maintain its dividend as its "1 capital allocation priority" [3] - It is alleged that after the acquisition, Organon shifted its capital allocation focus towards reducing debt rather than maintaining dividends [3] - The lawsuit also states that Organon failed to disclose the heightened risk of loss of exclusivity and price erosion related to its product Nexplanon [4]

Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its gene therapy treatment, ELEVIDYS, during the class period from June 22, 2023, to June 24, 2025 [1][2]. Allegations Against Defendants - The complaint claims that Sarepta made false or misleading statements and failed to disclose significant safety risks associated with ELEVIDYS [2]. - It is alleged that the trial protocols for ELEVIDYS did not adequately detect severe side effects, leading to potential regulatory scrutiny and halting of recruitment and dosing in trials [2]. - The severity of adverse events from ELEVIDYS treatment is said to have materially misled investors regarding the therapy's approval prospects [2]. Lead Plaintiff Process - Investors in Sarepta have until August 25, 2025, to seek appointment as a lead plaintiff, representing the class in the litigation [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest and who are representative of the class [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Insights - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025, amid commercial challenges and a class-action lawsuit [1][2][3] Leadership Transition - CFO Jean-Marc Bellemin's resignation aligns with his executive employment agreement and comes at a critical time for the company, which has not yet named a successor [2] - Bellemin has been in the CFO role since November 2020 [1] Commercial Challenges - Iovance's flagship drug, Amtagvi, has faced significant commercial setbacks, with first-quarter sales falling short of Wall Street expectations, leading to a revision of full-year revenue projections [3][6] - Following the disappointing sales figures and revenue guidance, Iovance's stock price dropped over 44%, from $3.17 to $1.75 per share within a day [7] Legal Issues - The company is defending against a class-action securities fraud lawsuit, which alleges misleading statements regarding the operational readiness of its authorized treatment centers (ATCs) crucial for Amtagvi's administration [4][5] - The lawsuit claims that ATCs have not been able to initiate treatments in a timely manner, leading to high patient drop-off rates [5] Market Reaction - The market reacted negatively to the company's underwhelming performance and the subsequent legal challenges, indicating investor concerns about Iovance's commercial execution and transparency [6][7] - Hagens Berman, a law firm, is investigating the allegations and the accuracy of Iovance's public statements regarding Amtagvi [8][9]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged misrepresentations regarding the safety risks of its product ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Sarepta and certain senior officers [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by August 25, 2025, with the option to remain as absent class members if they choose not to take action [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Core Viewpoint - PepGen Inc. is facing a securities fraud class action lawsuit alleging misrepresentations regarding the effectiveness and safety of its lead product candidate, PGN-EDO51, during a specified period [2][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased or acquired PepGen securities between March 7, 2024, and March 3, 2025 [2][3]. - Investors are reminded of an upcoming deadline to file as lead plaintiff by August 8, 2025, which allows them to represent other class members in the litigation [3]. Group 2: Legal Representation - Bernstein Liebhard LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [4]. - The firm has a strong track record, having recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its litigation success [5].

Core Viewpoint - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin amid commercial challenges and a class-action lawsuit related to its flagship drug Amtagvi [1][2][3]. Group 1: Leadership Transition - CFO Jean-Marc Bellemin will resign effective July 10, 2025, to pursue other endeavors, having held the position since November 2020 [1][2]. - The company has not yet named a successor for the CFO role, creating uncertainty during a challenging period [2]. Group 2: Commercial Challenges - Iovance's first-quarter sales for Amtagvi significantly underperformed expectations, leading to a revision of full-year revenue projections [3]. - The company attributed its disappointing results to "recent launch dynamics," including slow treatment timelines and higher-than-expected patient drop-off rates [6]. Group 3: Legal Issues - Iovance is facing a class-action lawsuit alleging securities fraud related to its portrayal of authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5]. - The lawsuit claims that the company misrepresented the operational efficiency of ATCs, which were reportedly experiencing delays and inefficiencies [5]. Group 4: Market Reaction - Following the disclosure of underwhelming first-quarter results and revised revenue guidance, Iovance's stock fell over 44%, from $3.17 to $1.75 per share within a day [7].

Group 1 - A complaint has been filed against Vestis Corporation in the United States District Court for the Southern District of New York, alleging violations of the Securities Exchange Act of 1934 [1] - The complaint involves investors who purchased or acquired Vestis securities between May 2, 2024, and May 6, 2025, claiming misrepresentations regarding the company's growth potential [1][3] - Bernstein Liebhard LLP, the law firm representing the investors, has a history of recovering over $3.5 billion for clients and has been recognized for its success in class action litigations [5] Group 2 - Investors interested in participating in the class action must file papers by August 8, 2025, to serve as lead plaintiff, although participation in recovery does not require this role [4] - The representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur fees or expenses unless there is a recovery [4]

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for alleged violations of the Securities Exchange Act of 1934, specifically regarding misrepresentations about the company's EBITDA targets for 2025 [1][2]. Group 1: Lawsuit Details - The complaint was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased Fortrea securities between July 3, 2023, and February 28, 2025 [1]. - The lawsuit alleges that the company and certain senior officers made misrepresentations concerning the company's financial targets [2]. Group 2: Legal Participation - Investors who wish to serve as lead plaintiffs must file necessary documents by August 1, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [3]. - All legal representation in this case is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented both individual investors and large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].